• Gavi, the Vaccine Alliance, has launched its "Gavi 6.0" strategy for 2026-2030, focusing on expanding global immunization efforts.

• Amid climate change and pandemics, Gavi will adjust co-financing and eligibility criteria to sustain immunization programs and enhance health security.

• The alliance aims to bolster vaccine manufacturing in Africa through the African Vaccine Manufacturing Accelerator (AVMA) and has set up a $500 million First Response Fund for rapid pandemic intervention.

• New vaccines for tuberculosis, dengue fever, group B streptococcus, hepatitis-E, and mpox have been approved, with COVID-19 vaccinations to phase out by 2025, shifting focus to emergency preparedness.

• Gavi remains committed to tackling outbreaks like measles and cholera, aligning with its mission to promote sustainable immunization and global health resilience.

• Shift towards emergency response mechanisms post-2025, with ongoing support for current outbreak responses, including mpox in the Democratic Republic of the Congo, are among the future COVID-19  plans.

• These decisions, finalized after a Geneva meeting, underscore Gavi's dedication to maximizing vaccine impact amidst evolving global health challenges.

Click here to read more.